• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Control Release . Thin-film freeze-drying of an influenza virus hemagglutinin mRNA vaccine in unilamellar lipid nanoparticles with blebs

tetano

Editor, Senior Moderator
J Control Release


. 2024 Sep 16:S0168-3659(24)00640-0.
doi: 10.1016/j.jconrel.2024.09.030. Online ahead of print. Thin-film freeze-drying of an influenza virus hemagglutinin mRNA vaccine in unilamellar lipid nanoparticles with blebs

Qin Li[SUP] 1 [/SUP], Ruiqi Shi[SUP] 1 [/SUP], Haiyue Xu[SUP] 2 [/SUP], Khaled AboulFotouh[SUP] 2 [/SUP], Molly M H Sung[SUP] 3 [/SUP], Thomas H Oguin[SUP] 4 [/SUP], Madeline Hayes[SUP] 4 [/SUP], Chaeho Moon[SUP] 2 [/SUP], Huy M Dao[SUP] 2 [/SUP], Houping Ni[SUP] 1 [/SUP], Sawittree Sahakijpijarn[SUP] 5 [/SUP], Chris Cano[SUP] 5 [/SUP], Gregory J Davenport[SUP] 5 [/SUP], Robert O Williams 3rd[SUP] 2 [/SUP], Jon Le Huray[SUP] 3 [/SUP], Zhengrong Cui[SUP] 6 [/SUP], Drew Weissman[SUP] 7 [/SUP]



Affiliations
Abstract

Messenger RNA (mRNA) vaccines have revolutionized the fight against infectious diseases and are poised to transform other therapeutic areas. Lipid nanoparticles (LNP) represent the most successful delivery system for mRNA. While the mRNA-LNP products currently in clinics are stored as frozen suspensions, there is evidence that freeze-drying mRNA-LNP into dry powders can potentially enable their storage and handling at non-freezing temperatures. Previously, we successfully applied thin-film freeze-drying (TFFD) to transform a polyadenylic acid [poly(A)]-LNP formulation from a liquid suspension to dry powders. The poly(A)-LNP were structurally multilamellar spheres without blebs, but the mRNA vaccines in clinics are comprised of mRNA-LNP that are structurally spheres surrounded by a unilamellar lipid bilayer, with some containing blebs, and it was reported that the presence of blebs increases the sensitivity of mRNA-LNP to freeze-drying-induced stress. In the present study, using an influenza A virus hemagglutinin (HA) mRNA in LNP that were structurally similar to that in the COVID-19 mRNA vaccines currently in clinic, we studied the effect of TFFD on the physical properties, internal structure, as well as immunogenicity of the HA mRNA-LNP vaccine. We concluded that TFFD can be utilized to prepare dry powders of the HA mRNA-LNP, but a sufficient amount of excipients were needed to minimize changes in the physical properties, structure, and immunogenicity of the HA mRNA-LNP vaccine.

Keywords: Freeze-drying; Immunogenicity; Lipid nanoparticles; Particle structure; mRNA.

 
Back
Top Bottom